Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice
- PMID: 17377815
- DOI: 10.1007/s00430-007-0043-4
Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice
Abstract
Domain III of Japanese encephalitis virus (JEV) envelope protein (E-DIII) was synthesized in E. coli as a fusion protein containing maltose-binding protein (MBP-E-DIII) or six contiguous histidine residues (His-E-DIII) at its N-terminus. MBP-E-DIII was found both in the soluble as well as the insoluble fraction of the bacterial lysate, while His-E-DIII was found exclusively in the inclusion bodies. These purified proteins were examined in mice for their immunogenicity in presence of an aluminium hydroxide based-adjuvant Alhydrogel and Freund's adjuvant. While both proteins generated anti-JEV antibodies that neutralized JEV activity in vitro, His-E-DIII generated higher antibody titers than MBP-E-DIII. Mice immunized with His-E-DIII in presence of Alhydrogel generated antibody titers similar to those induced by the commercial vaccine and protected mice against lethal JEV challenge.
Similar articles
-
[Immunogenicity and antigenicity of Japanese encephalitis virus envelope protein domain III].Sheng Wu Gong Cheng Xue Bao. 2009 Oct;25(10):1532-7. Sheng Wu Gong Cheng Xue Bao. 2009. PMID: 20112698 Chinese.
-
Oral immunization of mice with Japanese encephalitis virus envelope protein synthesized in Escherichia coli induces anti-viral antibodies.Microbes Infect. 2004 Nov;6(14):1305-11. doi: 10.1016/j.micinf.2004.08.010. Microbes Infect. 2004. PMID: 15555537
-
Antibodies against refolded recombinant envelope protein (domain III) of Japanese encephalitis virus inhibit the JEV infection to Porcine Stable Kidney cells.Protein Pept Lett. 2009;16(11):1334-41. doi: 10.2174/092986609789353709. Protein Pept Lett. 2009. PMID: 20001924
-
Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB/c mice.Vaccine. 2009 Nov 16;27(49):6905-9. doi: 10.1016/j.vaccine.2009.09.006. Epub 2009 Sep 15. Vaccine. 2009. PMID: 19761840
-
Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis.Microbes Infect. 2006 Jan;8(1):92-104. doi: 10.1016/j.micinf.2005.05.023. Epub 2005 Aug 9. Microbes Infect. 2006. PMID: 16126425
Cited by
-
Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.Vaccine. 2008 Jan 10;26(2):153-7. doi: 10.1016/j.vaccine.2007.10.055. Epub 2007 Nov 20. Vaccine. 2008. PMID: 18069096 Free PMC article.
-
Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.J Virol. 2011 Mar;85(5):1994-2003. doi: 10.1128/JVI.01886-10. Epub 2010 Dec 8. J Virol. 2011. PMID: 21147919 Free PMC article.
-
Selection and Characterization of DNA Aptamers Targeting All Four Serotypes of Dengue Viruses.PLoS One. 2015 Jun 25;10(6):e0131240. doi: 10.1371/journal.pone.0131240. eCollection 2015. PLoS One. 2015. PMID: 26110785 Free PMC article.
-
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer.J Hematol Oncol. 2025 Apr 17;18(1):43. doi: 10.1186/s13045-025-01694-2. J Hematol Oncol. 2025. PMID: 40247301 Free PMC article. Review.
-
West Nile virus: characterization and diagnostic applications of monoclonal antibodies.Virol J. 2012 Apr 13;9:81. doi: 10.1186/1743-422X-9-81. Virol J. 2012. PMID: 22500562 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous